Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Fosun Acquires Novel Cancer Immunotherapy in $125 Million Deal

publication date: May 23, 2022

Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. VerImmune’s Virus-Inspired Particle (ViP) technology attacks cancers by redirecting the body’s pre-existing immunity against viral pathogens from vaccinations and past infections. The ViPs are expected to create a response from existing immunity toward a broad range of tumors without the need to identify tumor antigens or generate tumor-specific immune responses. Fosun will pay VerImmune up to $125 million in upfront and milestone payments plus tiered royalties. More details...

Stock Symbols: (SHA: 600196; HK: 02196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital